Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 3/20 | 0.79 |
| ▸ | USP19 | O94966 | 2/20 | 0.79 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.79 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | USP8 | P40818 | 1/20 | 0.58 |
| ▸ | OTUB1 | Q96FW1 | 1/20 | 0.58 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29629184 | 0.88 | USP1 (1.00) | USP1USP19WDR48UCHL3USP2 | |
| SCHEMBL7808226 | 0.88 | USP1 (1.00) | USP1USP19WDR48UCHL3USP2 | |
| SCHEMBL29629183 | 0.88 | USP1 (1.00) | USP1USP19WDR48UCHL3USP2 | |
| SCHEMBL18203587 | 0.87 | USP1 (0.79) | USP1USP19WDR48UCHL3USP2 | |
| SCHEMBL7108416 | 0.84 | USP1 (0.64) | USP1USP19WDR48UCHL3USP2 | |
| SCHEMBL19220486 | 0.79 | USP1 (0.82) | USP1USP19WDR48UCHL3USP2 | |
| SCHEMBL7102799 | 0.77 | USP1 (0.54) | USP1USP19WDR48UCHL3USP2 | |
| SCHEMBL7815859 | 0.76 | USP1 (1.00) | USP1USP19WDR48UCHL3USP2 | |
| SCHEMBL7968066 | 0.76 | USP1 (0.77) | USP1USP19WDR48UCHL3USP2 | |
| SCHEMBL31276578 | 0.76 | USP1 (1.00) | USP1USP19WDR48UCHL3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-11717511-B2 | Pharmaceutical composition comprising derivative compound of 1,2-naphthoquinone for preventing or treating solid cancer or blood cancer | HUEN CO., LTD. (KR) | 2023-08-08 | — | — | US | disclosed |
| US-11717511-B2 | Pharmaceutical composition comprising derivative compound of 1,2-naphthoquinone for preventing or treating solid cancer or blood cancer | HUEN CO., LTD. (KR) | 2023-08-08 | — | — | US | disclosed |
| EP-4180034-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO Ltd. (KR) | 2023-05-17 | — | — | EP | disclosed |
| US-20210155596-A1 | PHARMACEUTICAL COMPOSITION COMPRISING DERIVATIVE COMPOUND OF 1,2-NAPHTHOQUINONE FOR PREVENTING OR TREATING SOLID CANCER OR BLOOD CANCER | HUEN CO., LTD. (KR) | 2021-05-27 | — | — | US | disclosed |
| US-10927085-B2 | 1,2-naphthoquinone based derivative and method of preparing the same | HUEN CO., LTD. (KR) | 2021-02-23 | — | — | US | disclosed |
| WO-2020246807-A2 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, CONTAINING NAPHTHOQUINONE COMPOUND | 주식회사 엘마이토테라퓨틱스 | 2020-12-10 | — | — | WO | disclosed |
| WO-2020242277-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES COMPRISING NAPHTHOQUINONE DERIVATIVE | 주식회사 엘마이토테라퓨틱스 | 2020-12-03 | — | — | WO | disclosed |
| US-20160376243-A1 | 1,2-NAPHTHOQUINONE BASED DERIVATIVE AND METHOD OF PREPARING THE SAME | KT&G LIFE SCIENCES CORPORATION (KR) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11717511-B2 | Pharmaceutical composition comprising derivative compound of 1,2-naphthoquinone for preventing or treating solid cancer or blood cancer | MCL1, SNX1, ABL1 | USP1 4163/4885USP19 3918/4885WDR48 3785/4885 |
| US-20210155596-A1 | PHARMACEUTICAL COMPOSITION COMPRISING DERIVATIVE COMPOUND OF 1,2-NAPHTHOQUINONE FOR PREVENTING OR TREATING SOLID CANCER OR BLOOD CANCER | MCL1, SNX1, ABL1 | USP1 4163/4885USP19 3918/4885WDR48 3785/4885 |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | PDCD1, CD274, PDCD10 | USP1 3747/4885USP19 2884/4885WDR48 3311/4885 |
| US-10927085-B2 | 1,2-naphthoquinone based derivative and method of preparing the same | UGT1A6, CYP2D6, SLC5A1 | USP1 2169/4885USP19 3941/4885WDR48 3219/4885 |
| US-20160376243-A1 | 1,2-NAPHTHOQUINONE BASED DERIVATIVE AND METHOD OF PREPARING THE SAME | CYP2S1, SLC5A1, CYP2D6 | USP1 2314/4885USP19 4085/4885WDR48 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.